B2B project has officially started on July 1, 2018. During the next 4 years, the Consortium will be busy developing a novel hybrid device able to model the spontaneous breast cancer metastasis to the bone. The project has been funded for a total of 3.8M€ under the FET OPEN call of the European Union’s Horizon 2020 Framework Programme. The full official information about the project is available in CORDIS.